ProCE Banner Activity

An Expert’s Guide to ASCO 2019: A Preview of the Top Abstracts

Clinical Thought
Experts highlight key studies being presented at the upcoming 2019 ASCO annual meeting in Chicago. The CCO ASCO Conference Coverage program will have the information you need to understand and integrate the latest oncology data into your practice.

Released: May 30, 2019

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Heather Wakelee

Heather Wakelee, MD

Associate Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro

Faculty Disclosure

Primary Author

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Tanios Bekaii-Saab MD, FACP, has disclosed that he served on independent data monitoring committees for Armo, AstraZeneca, and SillaJen.

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bayer, Celgene, Genentech, Gilead Sciences, Tempus, and Seattle Genetics and fees for non-CME/CE services from Seattle Genetics.

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambryx, Amgen, Bayer, Biomarin, Boehringer Ingelheim, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GlaxoSmithKline, Lilly, MacroGenics, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, Puma, Roche, and Seattle Genetics.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has served as a consultant for (paid to his institution) for AbbVie, Amgen, Celgene, Genentech, Janssen, Kite, MedImmune, Merck,, and Takeda and has received funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Sanofi, and Takeda. Also has served on data monitoring committee for oncopeptides.

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received funds for research support from Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Endocyte, Genentech, Innocrin, Lilly, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche, Sanofi, and Seattle Genetics; has received consulting fees from Advanced Accelerator Applications, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Exelixis, Incyte, Janssen, Lilly, Pfizer, Pharmacyclics, Roche, Seattle Genetics, and Urogen; and has ownership interest in Bellicum and Tyme.

Heather Wakelee, MD

Associate Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Heather Wakelee, MD, has disclosed that she has received consulting fees from AstraZeneca and Novartis and funds for research support paid to her institution from ACEA Biosciences, AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Clovis, Genentech/Roche, Gilead Sciences, Novartis, Pfizer, Pharmacyclics, and Xcovery.